Literature DB >> 17939331

The association between current Helicobacter pylori infection and coronary artery disease.

Seung-Won Jin1, Sung-Ho Her, Jong-Min Lee, Hee-Jeoung Yoon, Su-Jin Moon, Pum-Joon Kim, Sang-Hong Baek, Ki-Bae Seung, Jae-Hyung Kim, Sang-Bum Kang, Jae-Hi Kim, Keon-Yeop Kim.   

Abstract

BACKGROUND: The role of Helicobacter pylori (H. pylori) in the pathogenesis of coronary artery disease (CAD) is still controversial, and the relation between current H. pylori infection and CAD has not been fully examined. This study evaluated the relation between H. pylori infection as confirmed by gastroduodenoscopic biopsy and CAD.
METHODS: We determined the presence of H. pylori infections, via gastroduodenoscopy, in 88 patients of the normal coronary angiographic group and also in 175 patients of the CAD group, and the latter patients had more than 50% coronary stenosis angiographically demonstrated. We excluded those patients with a history of previous H. pylori eradication and/or malignancy. A small piece of tissue from the antrum, which was obtained by gastroduodenoscopic biopsy, was stained by Warthin-starry silver stain. We defined a negative staining result that there was no stained tissue in the sample and the stained tissue was also positive for H. pylori infection.
RESULTS: There was no significant difference, except for gender, age, smoking and high density lipoprotein cholesterol (HDL-c), of the demographic and laboratory characteristics between the groups. Twenty seven (30.7%) patients of the normal control group and 71 (40.6%) patients of the CAD group were positive of H. pylori infection, yet there was no statistical difference. We angiographically followed up the 80 patients of the CAD group who were treated by percutaneous coronary intervention (PCI) at 6 to 9 months after their primary intervention. Twenty two (37.9%) of the 58 patients of the H. pylori negative group and 10 (45.5%) of the 22 patients of the H. pylori positive group were treated with reintervention, but reintervention was also not significantly different between the group with H. pylori infection and the group without the infection.
CONCLUSIONS: These data indicated that H. pylori infection had a modest influence on CAD and progressive atheroma, but the showed a tendency to increase. Further studies are needed to evaluate the relationship between H. pylori infection and CAD.

Entities:  

Mesh:

Year:  2007        PMID: 17939331      PMCID: PMC2687700          DOI: 10.3904/kjim.2007.22.3.152

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  25 in total

1.  Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty.

Authors:  M Kowalski; P C Konturek; P Pieniazek; E Karczewska; A Kluczka; R Grove; W Kranig; R Nasseri; J Thale; E G Hahn; S J Konturek
Journal:  Dig Liver Dis       Date:  2001-04       Impact factor: 4.088

2.  Prevalence of coronary artery disease, ischemic stroke, peripheral arterial disease, and coronary revascularization in older African-Americans, Asians, Hispanics, whites, men, and women.

Authors:  J Ness; W S Aronow
Journal:  Am J Cardiol       Date:  1999-10-15       Impact factor: 2.778

Review 3.  Epidemiology of Helicobacter pylori infection.

Authors:  F Mégraud
Journal:  Gastroenterol Clin North Am       Date:  1993-03       Impact factor: 3.806

4.  Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis.

Authors:  Vincenzo Pasceri; Giuseppe Patti; Giovanni Cammarota; Christian Pristipino; Giuseppe Richichi; Germano Di Sciascio
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

5.  Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease.

Authors:  D H Thom; J T Grayston; D S Siscovick; S P Wang; N S Weiss; J R Daling
Journal:  JAMA       Date:  1992-07-01       Impact factor: 56.272

6.  Ischaemic heart disease and Cag A strains of Helicobacter pylori in the Caerphilly heart disease study.

Authors:  A F Stone; P Risley; H S Markus; B K Butland; D P Strachan; P C Elwood; M A Mendall
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

7.  Meta-analysis of the relationship between cagA seropositivity and gastric cancer.

Authors:  Jia Qing Huang; Ge Fan Zheng; Katica Sumanac; E Jan Irvine; Richard H Hunt
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Relation of Helicobacter pylori infection and coronary heart disease.

Authors:  M A Mendall; P M Goggin; N Molineaux; J Levy; T Toosy; D Strachan; A J Camm; T C Northfield
Journal:  Br Heart J       Date:  1994-05

9.  The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study.

Authors:  Agha W Haider; Peter W F Wilson; Martin G Larson; Jane C Evans; Eric L Michelson; Philip A Wolf; Christopher J O'Donnell; Daniel Levy
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

10.  Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease.

Authors:  R K Singh; A D McMahon; H Patel; C J Packard; B J Rathbone; N J Samani
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

View more
  13 in total

1.  Scintigraphic evaluation of gallbladder motor functions in H pylori positive and negative patients in the stomach with dyspepsia.

Authors:  Olga Taskaya Yaylali; Mustafa Yilmaz; Fatma Suna Kiraç; Serkan Değirmencioğlu; Metin Akbulut
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

2.  Association between Helicobacter pylori infection and angiographically demonstrated coronary artery disease: A meta-analysis.

Authors:  Xin-Juan Yu; Xuan Yang; Lei Feng; Li-Li Wang; Quan-Jiang Dong
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

Review 3.  Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.

Authors:  Jacek Budzyński; Marek Koziński; Maria Kłopocka; Julia Maria Kubica; Jacek Kubica
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

Review 4.  Infectious and coronary artery disease.

Authors:  Mohammad Saeid Rezaee-Zavareh; Mohammad Tohidi; Amin Sabouri; Mahdi Ramezani-Binabaj; Mohsen Sadeghi-Ghahrodi; Behzad Einollahi
Journal:  ARYA Atheroscler       Date:  2016-01

5.  Antibiotics for secondary prevention of coronary heart disease.

Authors:  Naqash J Sethi; Sanam Safi; Steven Kwasi Korang; Asbjørn Hróbjartsson; Maria Skoog; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-02-23

6.  Is helicobacter pylori infection a risk factor for coronary heart disease?

Authors:  Mehran Rogha; Marjan Nikvarz; Zahra Pourmoghaddas; Keivan Shirneshan; Davood Dadkhah; Masoud Pourmoghaddas
Journal:  ARYA Atheroscler       Date:  2012

7.  Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans.

Authors:  Hack-Lyoung Kim; Han Ho Jeon; In Young Park; Jin Man Choi; Ji Sun Kang; Kyueng-Whan Min
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

Review 8.  Helicobacter pylori infection and its relationship to metabolic syndrome: is it a myth or fact?

Authors:  Waleed I Albaker
Journal:  Saudi J Gastroenterol       Date:  2011 May-Jun       Impact factor: 2.485

9.  Association of helicobacter pylori infection with severity of coronary heart disease.

Authors:  Mehran Rogha; Davood Dadkhah; Zahra Pourmoghaddas; Keivan Shirneshan; Marjan Nikvarz; Masoud Pourmoghaddas
Journal:  ARYA Atheroscler       Date:  2012

10.  Association of Helicobacter pylori infection with coronary artery disease: is Helicobacter pylori a risk factor?

Authors:  Jamshid Vafaeimanesh; Seyyed Fakhroldin Hejazi; Vahid Damanpak; Mostafa Vahedian; Mohammadamin Sattari; Mohammadreza Seyyedmajidi
Journal:  ScientificWorldJournal       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.